Cationic Polyene Phospholipids as DNA Carriers for Ocular Gene Therapy
Open Access
- 1 January 2014
- journal article
- research article
- Published by Wiley in BioMed Research International
- Vol. 2014, 1-13
Abstract
Recent success in the treatment of congenital blindness demonstrates the potential of ocular gene therapy as a therapeutic approach. The eye is a good target due to its small size, minimal diffusion of therapeutic agent to the systemic circulation, and low immune and inflammatory responses. Currently, most approaches are based on viral vectors, but efforts continue towards the synthesis and evaluation of new nonviral carriers to improve nucleic acid delivery. Our objective is to evaluate the efficiency of novel cationic retinoic and carotenoic glycol phospholipids, designated C20-18, C20-20, and C30-20, to deliver DNA to human retinal pigmented epithelium (RPE) cells. Liposomes were produced by solvent evaporation of ethanolic mixtures of the polyene compounds and coformulated with 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) or cholesterol (Chol). Addition of DNA to the liposomes formed lipoplexes, which were characterized for binding, size, biocompatibility, and transgene efficiency. Lipoplex formulations of suitable size and biocompatibility were assayed for DNA delivery, both qualitatively and quantitatively, using RPE cells and a GFP-encoding plasmid. The retinoic lipoplex formulation with DOPE revealed a transfection efficiency comparable to the known lipid references 3β-[N-(N′,N′-dimethylaminoethane)-carbamoyl]-cholesterol (DC-Chol) and 1,2-dioleoyl-sn-glycero-3-ethylphosphocholine (EPC) and GeneJuice. The results demonstrate that cationic polyene phospholipids have potential as DNA carriers for ocular gene therapy.Keywords
Funding Information
- European Commission (PIRG-GA-2009-249314, PEst-OE/EQB/LA0023/2011, SFRH/BD/76873/2011, SFRH/BD/70318/2010, PTDC/SAU-BEB/0984754/2008, NPRP08-705-3-144)
- Fundação para a Ciência e a Tecnologia (PIRG-GA-2009-249314, PEst-OE/EQB/LA0023/2011, SFRH/BD/76873/2011, SFRH/BD/70318/2010, PTDC/SAU-BEB/0984754/2008, NPRP08-705-3-144)
- Fundação para a Ciência e a Tecnologia (PIRG-GA-2009-249314, PEst-OE/EQB/LA0023/2011, SFRH/BD/76873/2011, SFRH/BD/70318/2010, PTDC/SAU-BEB/0984754/2008, NPRP08-705-3-144)
- Fundação para a Ciência e a Tecnologia (PIRG-GA-2009-249314, PEst-OE/EQB/LA0023/2011, SFRH/BD/76873/2011, SFRH/BD/70318/2010, PTDC/SAU-BEB/0984754/2008, NPRP08-705-3-144)
- Fundação para a Ciência e a Tecnologia (PIRG-GA-2009-249314, PEst-OE/EQB/LA0023/2011, SFRH/BD/76873/2011, SFRH/BD/70318/2010, PTDC/SAU-BEB/0984754/2008, NPRP08-705-3-144)
- Qatar National Research (PIRG-GA-2009-249314, PEst-OE/EQB/LA0023/2011, SFRH/BD/76873/2011, SFRH/BD/70318/2010, PTDC/SAU-BEB/0984754/2008, NPRP08-705-3-144)
This publication has 28 references indexed in Scilit:
- Macular Pigment and Its Contribution to VisionNutrients, 2013
- Activation of retinal microglial cells is not associated with Müller cell reactivity in vitrectomized rabbit eyesActa Ophthalmologica, 2012
- Novel Cationic Carotenoid Lipids as Delivery Vectors of Antisense Oligonucleotides for Exon Skipping in Duchenne Muscular DystrophyMolecules, 2012
- Viral and nonviral delivery systems for gene deliveryAdvanced Biomedical Research, 2012
- Polymeric Vectors for Ocular Gene DeliveryTherapeutic Delivery, 2011
- Retinoid pathway and cancer therapeuticsAdvanced Drug Delivery Reviews, 2010
- Nanoparticles for retinal gene therapyProgress in Retinal and Eye Research, 2010
- Hydrophobic Moiety of Cationic Lipids Strongly Modulates Their Transfection ActivityMolecular Pharmaceutics, 2009
- Gene therapy for ocular angiogenesisClinical Science, 2003
- In Vitro Fusion of Reticulocyte Endocytic Vesicles with LiposomesJournal of Biological Chemistry, 1995